TR201908514T4 - İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ - Google Patents

İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ Download PDF

Info

Publication number
TR201908514T4
TR201908514T4 TR2019/08514T TR201908514T TR201908514T4 TR 201908514 T4 TR201908514 T4 TR 201908514T4 TR 2019/08514 T TR2019/08514 T TR 2019/08514T TR 201908514 T TR201908514 T TR 201908514T TR 201908514 T4 TR201908514 T4 TR 201908514T4
Authority
TR
Turkey
Prior art keywords
morfinane
derivatives
drug overdose
treatment
overdose treatment
Prior art date
Application number
TR2019/08514T
Other languages
English (en)
Inventor
Silverman Bernard
Fu Fen-Ni
Guo Chengyun
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of TR201908514T4 publication Critical patent/TR201908514T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans

Abstract

Mevcut uygulama, ilaç toksisitesi ve aşırı doz tedavisinde sürdürülebilir etkinliğe sahip Formül I'i içeren morfinan türevleri ile ilgilidir.
TR2019/08514T 2009-12-04 2010-10-13 İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ TR201908514T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26688109P 2009-12-04 2009-12-04

Publications (1)

Publication Number Publication Date
TR201908514T4 true TR201908514T4 (tr) 2019-07-22

Family

ID=44082631

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08514T TR201908514T4 (tr) 2009-12-04 2010-10-13 İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇

Country Status (19)

Country Link
US (4) US9119848B2 (tr)
EP (2) EP2506712B8 (tr)
JP (2) JP5691042B2 (tr)
AU (1) AU2010326676B2 (tr)
CA (1) CA2782529C (tr)
CY (1) CY1121646T1 (tr)
DK (1) DK2506712T3 (tr)
ES (1) ES2729679T3 (tr)
HR (1) HRP20191029T1 (tr)
HU (1) HUE043963T2 (tr)
LT (1) LT2506712T (tr)
ME (1) ME03468B (tr)
NZ (1) NZ600379A (tr)
PL (1) PL2506712T3 (tr)
PT (1) PT2506712T (tr)
RS (1) RS58894B1 (tr)
SI (1) SI2506712T1 (tr)
TR (1) TR201908514T4 (tr)
WO (1) WO2011068594A1 (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
US9119848B2 (en) * 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) * 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP2015504865A (ja) * 2011-12-15 2015-02-16 アルカーメス ファーマ アイルランド リミテッド オピオイドアゴニストと組み合わせたサミドルファン（ａｌｋｓ３３）
LT3153171T (lt) * 2011-12-15 2018-12-10 Alkermes Pharma Ireland Limited Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
CA2911231C (en) * 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
JP6360915B2 (ja) * 2014-06-13 2018-07-18 パーデュー、ファーマ、リミテッド、パートナーシップ アザモルフィナン誘導体及びその使用
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US9763572B2 (en) * 2015-02-17 2017-09-19 Children's Hospital Medical Center Quantitative pupillometry as a bedside predictor of postoperative respiratory depression
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES252980A1 (es) 1958-10-30 1960-11-01 Boehringer Sohn Ingelheim Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
CH581624A5 (tr) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2254298A1 (de) 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4161597A (en) 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
US4100228A (en) 1977-04-04 1978-07-11 The Dow Chemical Company Transparent impact styrene polymer structure
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4373139A (en) 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
US4374139A (en) 1981-11-09 1983-02-15 Hoffmann-La Roche Inc. Levorotatory N-substituted acylmorphinans useful as analgesic agents
DE3220831A1 (de) 1982-06-03 1983-12-08 Boehringer Ingelheim KG, 6507 Ingelheim N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4929622A (en) 1987-09-24 1990-05-29 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-Methanopyrrolo-3-benzazocines
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
AR005423A1 (es) 1996-01-10 1999-06-23 Smithkline Beecham Spa Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados.
GB9616253D0 (en) 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
ES2121553B1 (es) 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2001012197A1 (en) 1999-08-13 2001-02-22 Southern Research Institute Pyridomorphinans, thienomoprhinans and use thereof
PT1244447E (pt) 1999-11-29 2007-02-28 Adolor Corp Métodos e composições inovadoras envolvendo opióides e antagonístas opióides
ES2304477T3 (es) 2000-10-31 2008-10-16 Rensselaer Polytechnic Institute Procedimiento de preparacion de compuestos con afinidad a receptores opioides.
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
EP1485051B1 (en) 2002-03-20 2008-05-07 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20050222204A1 (en) 2002-05-30 2005-10-06 Mitch Charles H Opioid receptor antagonists
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
AU2002321720A1 (en) 2002-07-03 2004-01-23 Spinelix 3d microarray
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
US7271173B2 (en) 2002-11-18 2007-09-18 The Mclean Hospital Corporation Mixed kappa/mu opioids and uses thereof
WO2004071423A2 (en) * 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
KR20060134041A (ko) 2004-04-22 2006-12-27 모르 리서치 애플리케이션즈 리미티드 음식물 섭취 관리 방법
EA013261B1 (ru) 2004-05-14 2010-04-30 Янссен Фармацевтика, Н.В. Опиоидные соединения, замещенные карбоксамидогруппой
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
SI2251330T1 (sl) 2004-11-05 2012-09-28 Rensselaer Polytech Inst 4-hidroksibenzomorfani
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
ES2422579T3 (es) 2005-07-21 2013-09-12 Rensselaer Polytech Inst 2,6-Metano-3-benzazocinas 8-carboxamido sustituidas y 3-carboxamido morfanos sustituidos como ligandos de los receptores opioides
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
EP1983991A2 (en) * 2006-02-01 2008-10-29 Alkermes, Inc. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
NZ575620A (en) 2006-09-20 2010-11-26 Mallinckrodt Inc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
US20080234306A1 (en) 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
US20100130512A1 (en) 2007-05-16 2010-05-27 Rensselaer Polytechnic Institute Fused-ring heterocycle opioids
US8263807B2 (en) 2007-08-09 2012-09-11 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
CA2714331C (en) 2008-02-14 2016-08-09 Alkermes, Inc. Selective opioid compounds
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
ES2534055T3 (es) 2008-07-21 2015-04-16 Rensselaer Polytechnic Institute Opioides de amina no fenólicos con sustituyentes de gran tamaño
EP3170395A1 (en) * 2009-03-19 2017-05-24 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
WO2010141666A2 (en) 2009-06-04 2010-12-09 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US9119848B2 (en) 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
WO2011119605A2 (en) 2010-03-22 2011-09-29 Rensselaer Polytechnic Institute Carboxamide biosiosteres of opiates
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
ES2470315T3 (es) 2010-08-04 2014-06-23 Mallinckrodt Llc N-desmetilaci�n de 6-ceto morfinanos
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
EP2655332B1 (en) 2010-12-23 2016-07-13 Phoenix Pharmalabs, Inc. Novel morphinans useful as analgesics
LT3153171T (lt) 2011-12-15 2018-12-10 Alkermes Pharma Ireland Limited Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations

Also Published As

Publication number Publication date
CA2782529C (en) 2015-05-26
US20110136848A1 (en) 2011-06-09
CY1121646T1 (el) 2020-07-31
EP2506712B1 (en) 2019-03-27
HUE043963T2 (hu) 2019-09-30
PL2506712T3 (pl) 2019-09-30
JP2013512901A (ja) 2013-04-18
EP2506712A1 (en) 2012-10-10
EP2506712A4 (en) 2013-07-10
US9119848B2 (en) 2015-09-01
WO2011068594A1 (en) 2011-06-09
LT2506712T (lt) 2019-06-25
JP5691042B2 (ja) 2015-04-01
EP3569234A1 (en) 2019-11-20
AU2010326676A2 (en) 2012-08-30
ME03468B (me) 2020-01-20
JP6216305B2 (ja) 2017-10-18
PT2506712T (pt) 2019-05-31
EP2506712B8 (en) 2019-06-19
RS58894B1 (sr) 2019-08-30
SI2506712T1 (sl) 2019-06-28
CA2782529A1 (en) 2011-06-09
NZ600379A (en) 2014-05-30
AU2010326676B2 (en) 2013-03-14
AU2010326676A1 (en) 2012-06-21
US20170333422A1 (en) 2017-11-23
US20200345718A1 (en) 2020-11-05
US20160051535A1 (en) 2016-02-25
ES2729679T3 (es) 2019-11-05
DK2506712T3 (da) 2019-06-03
HRP20191029T1 (hr) 2019-09-20
JP2015038139A (ja) 2015-02-26

Similar Documents

Publication Publication Date Title
TR201908514T4 (tr) İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
MA33939B1 (fr) 5-alcynyl-pyrimidines
DE602008000754D1 (de) Tropanverbindungen
IN2012DN01233A (tr)
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
TR201708567T4 (tr) Sigma ligandların kemik kanseri ağrısında kullanımı.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
PH12015501088A1 (en) Dimeric compounds
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
MX2009004358A (es) Suministro transdermico de derivados polares de cetoprofeno.
TW200942530A (en) Pyridine compounds
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2011011767A (es) Combinacion antitumoral que comprende ave8062 y sorafenib.
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
CR10410A (es) Carboxamidas sustituidas.